Wedbush analyst Robert Driscoll initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX: